MADISON NASH: Open Payments
NPI 1407451271 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,924 in 54 payments from 16 companies in 2025. Trend: 2023 $907 · 2024 $722 · 2025 $1,924
Food & beverage: $1,892Education: $32
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $809 |
| Madrigal Pharmaceuticals | 3 | $228 |
| Eisai Inc. | 1 | $124 |
| GENZYME CORPORATION | 1 | $122 |
| Teva Pharmaceuticals USA, Inc. | 1 | $122 |
| Janssen Biotech, Inc. | 3 | $105 |
| Gilead Sciences, Inc. | 1 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $63 |
| PFIZER INC. | 2 | $51 |
| Aimmune Therapeutics, Inc. | 2 | $44 |
Products named: SKYRIZI, REZDIFFRA, RINVOQ, Leqembi, DUPIXENT, TREMFYA, Livdelzi, ENTYVIO.
Industry payments across TX — which companies pay providers there.
